A Comprehensive Study of SARS-CoV-2: From 2019-nCoV to COVID-19 Outbreak

키워드

참고문헌 (112)

1. Shereen MA, "COVID-19 infection : Origin, transmission, and characteristics of human coronaviruses", J. Adv. Res, 24, pp.91~98 (2020)
2. Zhong NS, "Epidemiology and cause of severe acute respiratory syndrome(SARS)in Guangdong, People's Republic of China, in February, 2003", Lancet, 362, pp.1372~1358 (2003)
3. Wang N, "Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4", Cell Res, 23, pp.986~993 (2013)
4. Waris A, "COVID-19 outbreak : current scenario of Pakistan", New Microbes New Infect, 35, pp.100681~ (2020)
5. Cui J, "Origin and evolution of pathogenic coronaviruses", Nat. Rev. Microbiol, 17, pp.181~192 (2019)
6. Lai CC, "Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and corona virus disease-2019(COVID-19) : the epidemic and the challenges", Int. J. Antimicrob. Agents, 55, pp.105924~ (2020)
7. Zhao S, "Preliminary estimation of the basic reproduction number of novel coronavirus(2019-nCoV)in China, from 2019 to 2020 : A datadriven analysis in the early phase of the outbreak", Int. J. Inf. Dis, 92, pp.214~217 (2020)
8. "Structure of SARS-CoV-2"[URL]
9. Gorbalenya AE, "Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group", BioRxiv, ~ (2020)
10. Li Q, "Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia", N. Engl. J. Med, 382, pp.1199~1207 (2020)
11. Wang C, "A novel coronavirus outbreak of global health concern", Lancet, 395, pp.470~473 (2020)
12. Wang J, "Strengths, weaknesses, opportunities and threats(Swot)analysis of china’s prevention and control strategy for the covid-19 epidemic", Int. J. Environ. Res. Pub. Health, 17, pp.2235~ (2020)
13. Ebrahim SH, "Covid-19 and community mitigation strategies in a pandemic", BMJ, 368, pp.m1066~ (2020)
14. "Coronavirus disease 9COVID-19)Pandemic"[URL]
15. Tang XC, "Prevalence and genetic diversity of coronaviruses in bats from China", J. Virol, 80, pp.7481~7490 (2006)
16. Ksiazek TG, "A novel coronavirus associated with severe acute respiratory syndrome", N. Eng. J. Med, 348, pp.1953~1966 (2003)
17. Guan Y, "Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China", Science, 302, pp.276~278 (2003)
18. Guan Y, "Severe acute respiratory syndrome", pp.79~83 (2005), Blackwell Pub
19. Kan B, "Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms", J. Virol, 79, pp.11892~11900 (2005)
20. Li W, "Bats are natural reservoirs of SARS-like coronaviruses", Science, 310, pp.676~679 (2005)
21. Eaton BT, "Introduction to current focus on Hendra and Nipah viruses", Microbes Infect, 3, pp.277~278 (2001)
22. Giwa AL, "Novel coronavirus COVID-19 : an overview for emergency clinicians", Pediatr. Emerg. Med. Pract, 22, pp.1~21 (2020)
23. Tang XC, "Prevalence and genetic diversity of coronaviruses in bats from China", J. Virol, 80, pp.7481~7490 (2006)
24. Holshue ML, "First case of 2019 novel coronavirus in the United States", N. Eng. J. Med, 382, pp.929~936 (2020)
25. Zhou D, "Emerging understanding of etiology and epidemiology of the novel coronavirus(COVID-19)infection in Wuhan, China", ~ (2020)
26. Kraay AN, "Fomite-mediated transmission as a sufficient pathway : a comparative analysis across three viral pathogens", BMC Infect. Dis, 18, pp.540~ (2018)
27. Chen H, "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women : a retrospective review of medical records", Lancet, 395, pp.809~815 (2020)
28. Zhou P, "Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin", BioRxiv, 914952~ (2020)
29. Graham RL, "Recombination, reservoirs, and the modular spike : mechanisms of coronavirus cross-species transmission", J. Virol, 84, pp.3134~3146 (2010)
30. Li W, "Bats are natural reservoirs of SARS-like coronaviruses", Science, 310, pp.676~679 (2005)
31. Wilson DE, "Mammal species of the world: a taxonomic and geographic reference", pp.1~ (2005), JHU Press
32. Chu DKW, "Coronaviruses in bent-winged bats (Miniopterus spp.)", J. Gen. Virol, 87, pp.2461~2466 (2006)
33. Page RD, "Parallel phylogenies : reconstructing the history of host-parasite assemblages", Cladistics, 10, pp.155~173 (1994)
34. Cui J, "Evolutionary relationships between bat coronaviruses and their hosts", Emerg. Infect. Dis, 13, pp.1526~1532 (2007)
35. Zhou P, "Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin", BioRxiv, 914952~ (2020)
36. Lv L, "Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13", BioRxiv, ~ (2020)
37. Zhang T, "Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak", Curr. Biol, 30, pp.1578~ (2020)
38. Sabino-Silva R, "Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis", Clin. Oral Invesig, 24, pp.1619~1621 (2020)
39. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
41. Guo YR, "The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19)outbreak–an update on the status", Mil. Med. Res, 7, pp.11~ (2020)
42. Lipsitch M, "Defining the epidemiology of Covid-19—studies needed", N. Eng. J. Med, 382, pp.1194~1196 (2020)
43. Wu P, "Realtime tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22January 2020", Euro Surveill, 25, pp.2000044~ (2020)
44. Kim H, "Outbreak of novel coronavirus (COVID-19): What is the role of radiologists?", Eur. Radiol, 30, pp.3266~3267 (2020)
45. Novel CPERE, "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases(COVID-19)in China", CCDC Weekly, 1~5 (2020)
46. Chang D, "Protecting health-care workers from subclinical coronavirus infection", Lancet Respir. Med, 8, pp.e13~ (2020)
47. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
48. Guan WJ, "Clinical characteristics of 2019 novel coronavirus infection in China", N. Engl. J. Med, 382, pp.1708~1720 (2020)
49. Liu J, "Neutrophil-tolymphocyte ratio predicts severe illness patients with 2019novel coronavirus in the early stage", J. Transl. Med, 18, pp.206~ (2020)
50. Jiang F, "Review of the clinical characteristics of coronavirus disease 2019(COVID-19)", J. Gen. Intern. Med, 45, pp.1545~1549 (2020)
51. Lai CC, "Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and corona virus disease-2019(COVID-19) : the epidemic and the challenges", Int. J. Antimicrob. Agents, 55, pp.105924~ (2020)
52. Corman VM, "Detection of 2019 novel coronavirus(2019-nCoV)by real-time RT-PCR", Euro Surveill, 25, pp.2000045~ (2020)
53. Wang W, "Updated understanding of the outbreak of 2019 novel coronavirus(2019-nCoV)in Wuhan, China", J. Med. Virol, 92, pp.441~447 (2020)
54. Peiris JSM, "Severe acute respiratory syndrome", Nat. Med, 10, pp.S88~S97 (2004)
55. De Wit E, "SARS and MERS : recent insights into emerging coronaviruses", Nat. Rev. Microbiol, 14, pp.523~534 (2016)
56. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
57. Li X, "Molecular immune pathogenesis and diagnosis of COVID-19", J. Pharma. Anal, 10, pp.102~108 (2020)
58. Belouzard S, "Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites", Proc. Natl. Acad. Sci. USA, 106, pp.5871~5876 (2009)
59. Millet JK, "Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein", Proc. Natl. Acad. Sci. USA, 111, pp.15214~15219 (2014)
60. Wang H, "SARS coronavirus entry into host cells through a novel clathrinand caveolae-independent endocytic pathway", Cell Res, 18, pp.290~301 (2008)
61. Barth H, "Novel vaccine strategies", Symposium, 30, pp.214~228 (2004)
62. Zheng B, "SARSCoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection", Cell Bio. Int, 1, pp.25~28 (2010)
63. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
64. Liu J, "Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients", EBioMedicine, 55, pp.102763~ (2020)
65. Meduri GU, "Inflammatory cytokines in the BAL of patients with ARDS : persistent elevation over time predicts poor outcome", Chest, 108, pp.1303~1314 (1995)
66. Goodman RB, "Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome", Am. J. Respir. Crit. Care Med, 154, pp.602~611 (1996)
67. Zenewicz LA, "IL-22 : there is a gap in our knowledge", ImmunoHorizons, 2, pp.198~207 (2018)
68. Wu D, "TH17 responses in cytokine storm of COVID-19 : An emerging target of JAK2 inhibitor Fedratinib", J. Microbiol. Immunol. Infect, 53, pp.368~370 (2020)
69. Li F, "Receptor recognition mechanisms of coronaviruses : a decade of structural studies", J. Virol, 89, pp.1954~1964 (2015)
70. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2spike glycoprotein", Cell, 181, pp.281~292 (2020)
71. Hoffmann M, "The novel coronavirus 2019(2019-nCoV)uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells", BioRxiv, 1~5 (2020)
72. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
73. Zou X, "Single-cell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection", Front. Med, 14, pp.185~192 (2020)
74. Fang Y, "Sensitivity of chest CT for COVID-19 : comparison to RT-PCR", Radiology, 296, pp.E115~E117 (2020)
75. Pan F, "Time course of lung changes on chest CT during recovery from 2019 novel coronavirus(COVID-19)pneumonia", Radiology, 295, pp.200370~ (2020)
76. Wang Y, "Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak", J. Med. Virol, 92, pp.538~539 (2020)
77. Chu DK, "Molecular diagnosis of a novel coronavirus(2019-nCoV)causing an outbreak of pneumonia", Clin. Chem, 66, pp.549~555 (2020)
78. Pan Y, "Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia(2019-nCoV) : a study of 63 patients in Wuhan, China", Eur. Radiol, 30, pp.3306~3309 (2020)
79. Shi H, "Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus(2019-nCoV)pneumonia in Wuhan, China", Radiology, 295, pp.20~ (2020)
80. Chung M, "CT imaging features of 2019 novel coronavirus(2019-nCoV)", Radiology, 295, pp.202~207 (2020)
81. Zhao R, "Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-expressed full-length SARS-CoV-2 S1 proteins", medRxiv, 1~11 (2020)
82. Waris A, "Role of nanotechnology in diagnosing and treating COVID-19 during the Pandemic", Intl’ J. Clin. Virol, 4, pp.65~70 (2020)
83. Pan Y, "Serological immunochromatographic approach in diagnosis with SARSCoV-2 infected COVID-19 patients", J. Inf, 81, pp.28~32 (2020)
84. Tang Y-W, "Laboratory diagnosis of COVID-19 : current issues and challenges", J. Clin. Microbiol, 58, pp.512~520 (2020)
85. Yong SEF, "Connecting clusters of COVID-19 : an epidemiological and serological investigation", Lancet Inf. Dis, 20, pp.809~815 (2020)
86. Guo YR, "The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19)outbreak–an update on the status", Mil. Med. Res, 7, pp.11~ (2020)
87. Bhatraju PK, "Covid-19 in critically ill patients in the Seattle region—case series", N. Eng. J. Med, 382, pp.2012~2022 (2020)
88. Devaux CA, "New insights on the antiviral effects of chloroquine against coronavirus : what to expect for COVID-19?", Int. J. Antimicrob. Agents, 55, pp.105938~ (2020)
89. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
90. Boriskin YS, "A broad-spectrum antiviral compound that blocks viral fusion", Curr. Med. Chem, 15, pp.997~1005 (2008)
91. Wu R, "An update on current therapeutic drugs treating COVID-19", Curr. Pharm. Rep, 11, pp.1~ (2020)
92. Sheahan TP, "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERSCoV", Nat. Com, 11, pp.1~4 (2020)
93. Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, doubleblind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
94. Tao YY, "Treatments in the COVID-19 pandemic : an update on clinical trials", Expert Opin. Emerg. Drug, 25, pp.81~88 (2020)
95. Owens B, "Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology", The Lancet Rheum, 2, pp.e257~ (2020)
96. Singh AK, "Chloroquine and hydroxychloroquine in the treatment of COVID-19with or without diabetes : A systematic search and a narrative review with a special reference to India and other developing countries", Diabetes & Metabolic Syndrome : Clin. Res. Rev, 14, pp.241~246 (2020)
97. Jha AK, "Emerging treatment and prevention strategies against COVID-19 : a brief update", J. Dig. Endos, 11, pp.69~72 (2020)
98. Gao J, "Breakthrough : Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19associated pneumonia in clinical studies", Biosci. Tren, 14, pp.72~73 (2020)
99. Szekely Y, "Chloroquine-induced torsade de pointes in a COVID-19patient", Heart Rhythm, 17, pp.1~4 (2020)
100. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
101. Wu J, "Clinical characteristics of imported cases of COVID-19 in Jiangsu province : a multicenter descriptive study", Clin. Inf. Dis, 71, pp.706~712 (2020)
102. Luo H, "Can Chinese medicine be used for prevention of corona virus disease 2019(COVID-19)? A review of historical classics, research evidence and current prevention programs", Chin. J. Integr. Med, 26, pp.243~250 (2020)
103. Pang J, "Potential rapid diagnostics, vaccine and therapeutics for 2019novel Coronavirus(2019-ncoV) : a systematic review", J. Clin. Med, 9, pp.623~ (2020)
104. Casadevall A, "The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases", PLoS Pathog, 11, pp.e1004717~ (2015)
105. "COVID-19 treatment and vaccine Tracker" (2020)[URL]
106. "COVID-19 information hub"[URL]
107. "Coronavirus (Covid-19) Vaccine Latest Update" (2020)[URL]
108. "Moderna. Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19"[URL]
109. Mullard A, "COVID-19 vaccine development pipeline gears up", Lancet, 395, pp.1751~1752 (2020)
110. Lai CC, "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents", Int. J. Antimicrob. Agents, 55, pp.105924~ (2020)
111. Lai MM, "Recombination in large RNA viruses : coronaviruses", Virol, 7, pp.381~388 (1996)
112. Lai CC, "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2(SARSCoV-2) : Facts and myths", J. Microbiol. Immunol. Infect, 53, pp.404~412 (2020)

관련 논문AI추천